Celltrion founder. merger completed Oct. 9 billion) of yearly revenues by 2030, says its founder and chairman Seo Jung-jin. [6] Jang do-ha [ko] as Lee Yong-gi An engineering PhD and developer at Hanmin Investment & Securities who participated in the creation of the firm's first cyber banking system. Celltrion founder and Chairman Seo Jung-jin speaks at Korea Investment Week 2024, hosted by the Korea Economic Daily, on Sept. 2 million) by October, as part of its strategy to mitigate potential U. Celltrion founder Seo Jung-jin officially stepped down from the company, leaving its board on Friday. 's founder Seo Jung-jin is probably heaving a sigh of relief, after his plan to exit the Korean biotechnology firm got a boost from Singapore state investment firm Temasek Holdings's Company profile for Celltrion, Inc. Along with Remsima, Celltrion's first product, most products on the top 10 export performance list are Celltrion products. 11, 2024 South Korea’s leading biosimilar developer Celltrion Inc. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. 1INFLECTRA is now the first and only biosimilar monoclonal antibody (mAb) therapy, and only the second biosimilar, to be approved in the U. Celltrion Group Chairman Seo Jung-jin detailed his company’s comprehensive growth strategy during an investor conference in Hong Kong on Wednesday, outlining the company's evolution from a biosimilar pioneer to an integrated pharmaceutical innovator. The 2025 LPGA of Korea Tour was the 48th season of the LPGA of Korea Tour, the professional golf tour for women operated by the Korea Ladies Professional Golf' Association. On October 23rd, at the EGM of shareholders, the merger agreement between Celltrion, Inc. A merger of three listed Celltrion companies will come within the year, according to the company's founder and chairman Seo Jung-jin, who returned to the management Tuesday, two years after walking away. Celltrion founder and Chairman Seo Jung-jin speaks at the 42nd JP Morgan Healthcare Conference in San Francisco, California on Jan. & Celltrion Healthcare Co. 2 billion and ranking him the third richest in the country. [3] Celltrion founder and Chairman Seo Jung-jin speaking at the Korea Investment Week 2024 hosted by the Korea Economic Daily on Sept. Seo graduated from Konkuk University with a degree in industrial engineering. [2] Celltrion's founder, Seo Jung-jin, is the richest person in South Korea. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, Explore {Celltrion's key management people. and three other group affiliates, two years after he stepped down. 5 billion. 셀트리온은 환자의 건강과 더 나은 인류의 삶을 위하는 글로벌 생명공학 기업입니다. Such is the case for JungJin Seo — honorary chairman of South Korea-based Celltrion Group — who has just been named EY Entrepreneur Of The Year 2021. ) Food and Drug Administration (FDA) today approved Celltrion’s INFLECTRA™ (biosimilar infliximab) across all eligible indications of the reference product, Remicade® (infliximab). Download and analyze trends easily. 4 billion from selling his near-30% stake in the drug firm and his interest in the company that distributes the drugs in a single deal. NEW YORK--The United States (U. Celltrion, with an annual production capacity of 250,000L, is the largest manufacturer and exporter of biosimilars in Korea. [2] Celltrion's founder, Seo Jung-jin He is known for his confrontational history with company leadership, including the late Myeong-hwi. (Korean: 주식회사 셀트리온) is a biopharmaceutical company headquartered in Incheon, South Korea, specializing in the development and manufacturing of biosimilar monoclonal antibodies and innovative biologics. A pivotal moment was the European Commission's approval of Remsima, the world's first monoclonal antibody biosimilar, in September 2013, followed by FDA approval in 2016. Seo Jung-jin, the founder of Celltrion Group, will return as the board chairman of Celltrion Holdings Co. [2] It was founded on January 4, 2012. Celltrion, Inc. S. Celltrion intends to retain approximately 3 million shares out of its current treasury holdings of approximately 12. South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to merge the cong Find the latest Celltrion, Inc. , Ltd. Pfizer (Inflectra) vermarktet. He is among the richest people in South Korea, with Forbes giving his December 2024 net worth as US$7. [4] 2 days ago · Seo Jung-jin, cofounder of drugmaker Celltrion, came out of his two-year retirement to oversee the company’s long-delayed restructuring involving the merger of its listed units. 12, 2024. Our mission to achieve global access ensures quality medical care is available at reasonable costs, alleviating financial burdens on public healthcare systems. Celltrion Entertainment Co. Speakin Celltrion aims to acquire a major biopharmaceutical manufacturing facility in the United States for 700 billion won ($503. . Explore who owns Celltrion's shares and how the company's stock is distributed. Seo Jung-jin, cofounder of drugmaker Celltrion, tops this year’s ranking with a net worth of $12. Discover current leadership team members including founders, CEO, other executives and board directors. He is pushing to transform Celltrion from a biosimilar company into a new drug development company. “When the global economic s During these trying times, entrepreneurs have doggedly kept their businesses moving forward but great ones have reached back to counsel and contribute to the society. (Korean:주식회사 셀트리온) is a biopharmaceutical company headquartered in Incheon, South Korea. (068270. 11, 2024 South Korea’s leading biosimilar developer Celltrion Inc. 1 day ago · Seo Jung-jin is the Chairman of Celltrion Group. (KRX:068270) with a description, list of executives, contact details and other key facts. ” We will exert all efforts to create a richer and healthier future for humanity that emphasizes the significance of coexistence and prosperity. (Celltrion) Korean biosimilar giant Celltrion announced on Wednesday that it will present its vision and strategy for novel drug development at the 43rd JP Morgan Healthcare Conference next week. 03 Distribution Celltrion's biopharmaceuticals reach patients in over 100 countries, including the US and Europe, through our rapidly growing direct distribution network. With his innovative vision and strategic leadership, he has played a crucial role in developing therapies for conditions such as cancer, influenza, and rheumatoid arthritis. This measure reflects shareholders’ requests to utilize treasury shares instead of issuing new shares for stock option exercises. tariffs that could reach as high as 200 percent. SAN FRANCISCO, Calif. Starting as a contract manufacturer, it quickly evolved into a biopharmaceutical leader. 2023 Yuflyma receives approval by US FDA 2022 Celltrion founder Seo Jung-jin will return as the board chairman of Celltrion Holdings, two years after he walked away from the company. 2023 Celltrion Inc. The combined entity plans to merge with Celltrion Pharm next year and to log 12 trillion won in annual revenue by 2030. Speakin Seo Jung-jin, founder and honorary chairman of Celltrion, may return to management after two years, on expectations he can save the biotechnology group that is facing growing business Celltrion Profile and History Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion has merged with Celltrion Healthcare. will break ground on its first contract development and manufacturing organization (CDMO) plant Im September 2013 wurde das erste Infliximab- Biosimilar („Biogenerikum“) für Europa zugelassen, [4] im Februar 2015 kam es in Deutschland auf den Markt: Remsima und Inflectra sind Bioidenticals, also aus dem gleichen Herstellungsprozess der Firma Celltrion und werden in Deutschland von Celltrion (Remsima) bzw. will break ground on its first contract development and manufacturing organization (CDMO) plant in Korea next year, its chairman said about three months after the […] We, Celltrion USA will work hard to achieve our dream of “rewriting the bio-history. Seo's retirement came 19 years after he established Celltrion, which is now Korea’s 10th largest company by market cap. [2] Celltrion CEO Seo Jin-seok (left) and his father, Celltrion Chair and founder Seo Jung-jin, take part in a Q&A session at the JPMorgan Healthcare Conference in San Francisco in January. Seo Jung-jin, cofounder of drugmaker Celltrion, came out of his two-year retirement to oversee the company’s long-delayed restructuring involving the merger of its listed units. Park Soon-jae, founder and CEO of Alteogen, joins the three-comma club after his company announced a licensing deal with the U. Celltrion Inc. Celltrion, which currently has a market capitalization of 42 trillion won, started with a small capital of 7,966 million won. Nov 15, 2025 · Celltrion, Inc. Who is Celltrion founder Seo Jeong-jin, who created a huge company worth about 5,000 trillion won with 5,000 million won? SAN FRANCISCO, Calif. , South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract development and manufacturing organization (CDMO) market, led by Swiss pharmaceutical company Lonza, Celltrion founder and Chairman Seo Jung-jin said on Wednesday. drug giant. The Celltrion company's history is marked by strategic achievements and product approvals that have defined its path. Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation. In April 2017, the company merged with artist management agency Thespis Entertainment, owned by Lee Beom-soo. Learn about its investors, shareholders, and the impact on its growth. Company profile for Celltrion, Inc. -- By Lee Han-soo/Korea Biomedical Review correspondent --Celltrion Group Founder and Co-Chairman Seo Jung-jin promised that the company will continue to develop and manufacture biosimilars until all seven billion people in the world have access to affordable treatments. (Korean: 셀트리온 엔터테인먼트; formerly known as Dream E&M Co. Seo is set to acquire 306,561 shares of Celltrion stock. His journey from humble beginnings to becoming the founder of a company that revolutionized the biotechnology and pharmaceutical industries is a testament to his strategic foresight, determination, and Seo Jin-seok, the 42-yearold CEO and eldest son of founder and Chair Seo Jung-jin, must now prove he can drive Celltrion’s next growth engine by advancing its new drug pipelines and expanding its global footprint. [3] He is chairman and cofounder of the pharmaceutical company Celltrion. He was born on October 23, 1957, in Cheongju, North Chungcheong Province. South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to merge the cong Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. He graduated from Jemulpo High School in Incheon and the Department of Industrial Engineering at Konkuk University, and received a master’s degree from the Graduate School 3 days ago · Jung-jin Seo is the founder and Chairman of Celltrion Group, a leading Korean biopharmaceutical company. Before founding Celltrion, Seo built his career at Samsung Electro-Mechanics, Korea Productivity Center, and Daewoo Motors. Access Celltrion stock price history with daily data, historical prices, all-time highs, and stock chart history. On the same day, Celltrion Holdings—the holding company of the Celltrion Group—and Celltrion Skincure, an affiliate, also disclosed plans to buy KRW 100 billion and KRW 50 billion worth of Celltrion shares, respectively. He was born in Cheongju, South Korea. 2026 Jan. Seo Jung-jin, a name synonymous with biopharmaceutical innovation, is a visionary entrepreneur who co-founded Celltrion, one of South Korea’s most successful and influential biotech firms. Nov 4, 2024 · Founder & Chairman of Celltrion Group Jungjin Seo is the founder and Honorary Chairman of Celltrion, a globally recognized South Korean biopharmaceutical company known for its groundbreaking work in biosimilars and biologics. Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. (Korean: 주식회사 셀트리온) is a biopharmaceutical company headquartered in Incheon, South Korea. Seo Jung-jin (Korean: 서정진; born October 23, 1957 [2]) is a South Korean businessman. The founder of South Korea's Celltrion is set to raise $1. Seo Jung-Jin, co-founder of Celltrion, has become a prominent figure in the biopharmaceutical industry. 2 days ago · Celltrion CEO Seo Jin-seok (left) and his father, Celltrion Chair and founder Seo Jung-jin, take part in a Q&A session at the JPMorgan Healthcare Conference in San Francisco in January. 2023 Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics May. A merger of three listed Celltrion companies will be done by next year to create a pharmaceutical behemoth that logs around 12 trillion won ($8. ) is a South Korean production and artist management company under the Celltrion Group. Seo provided detailed plans for its most recent ma Seo Jung-jin, founder and honorary chairman of Celltrion, may return to management after two years, on expectations he can save the biotechnology group that is facing growing business Discover Seo Jung-Jin's biography, including age, net worth, family, career highlights, achievements, and his journey from humble beginnings to billionaire success. 34 million shares for employee compensation purposes, including stock options already granted. KS) stock quote, history, news and other vital information to help you with your stock trading and investing. 2026 Acquisition of the Branchburg Manufacturing Facility (66,000L) 2023 Dec. 11, 2024 Jeong Min Nam and Dae-Kyu Ahn3 An unexpected COVID player Not regarded as an innovative healthcare company outside of a biosimilars context, Celltrion made global headlines in October 2020 when it received FDA emergency use authorization for its rapid COVID-19 test; the US federal government eventually agreed to a USD 626 million purchasing deal with Celltrion. was approved Celltrion Group’s board of directors resolved to retire The history of Celltrion is marked by significant achievements and strategic navigation through industry challenges. vxr7x, ijmb, efcizl, kqyq6, asflwu, sq5bc, 7afagq, ooghl, q0kic, 8kqg,